The economic impact of treating deep vein thrombosis with low- molecular-weight heparin: Outcome of therapy and health economy aspects: Low- molecular-weight heparin versus unfractionated heparin

Haemostasis

Volumn 28, Issue SUPPL. 3, 1998, Pages 8-16

  Hull, Russell D ^a,c   Pineo, Graham F ^a   Raskob, Gary E ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF OKLAHOMA   (United States)

^c FOOTHILLS HOSPITAL   (Canada)

Author keywords

Cost effectiveness; Deep vein thrombosis; Health economy; Low molecular weight heparin; Venous thromboembolism

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN;

BRAIN HEMORRHAGE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE POLICY; HEMATEMESIS; HEMATOMA; HEMATURIA; HUMAN; MELENA; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTICOAGULANTS; COSTS AND COST ANALYSIS; DOUBLE-BLIND METHOD; EVALUATION STUDIES; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; THROMBOPHLEBITIS;

EID: 0032448601     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (54)

1. Rabinov K, Paulin S: Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972;104:134-144.
2. Wheeler HB, O'Donnell JA, Anderson FA Jr, Benedict K Jr: Occlusive impedance plethysmography: a diagnostic procedure for venous thrombosis and pulmonary embolism. Prog Cardiovasc Dis 1974;17:199-205.
3. Hull RD, Hirsh J, Sackett DL, Powers P, Turpie AGG, Walker I: Combined use of leg scanning and impedance plethysmography in suspected venous thrombosis: an alternative to venography. N Engl J Med 1977;296:1497-1500.
4. Hull RD, Carter CJ, Jay RM, Ockleford PA, Hirsh J, Turpie AG, Zielinsky A, Gent M, Powers PJ: The diagnosis of acute, recurrent, deep-vein thrombosis: a diagnostic challenge. Circulation 1983;67:901-906.
5. Dalen JE, Brooks HL, Johnson LW, Meister SG, Szucs MM Jr, Dexter L: Pulmonary angiography in acute pulmonary embolism: indications, techniques, and results in 367 patients. Am Heart J 1971;81:175-185.
6. Salzman EW, Deykin D, Shapiro RM, Rosenberg R: Management of heparin therapy: controlled prospective trial. N Engl J Med 1975;292:1046-1050.
7. Glazier RL, Crowell EB: Randomized prospective trial of continuous vs intermittent heparin therapy. JAMA 1976;236:1365-1367.
8. Mant MJ, O'Brien BD, Thong KL, Hammond GW, Birtwhistle RV, Grace MG: Haemorrhagic complications of heparin therapy. Lancet 1977;1:1133-1135.
9. Wilson JR, Lampman J: Heparin therapy: a randomized prospective study. Am Heart J 1979;97:155-158.
10. Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH, Rosenbloom D, Sackett DL, Anderson C, Harrison L: Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315:1109-1114.
11. Hull RD, Delmore T, Genton E, Hirsh J, Gent M, Sackett D, McLoughlin D, Armstrong P: Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979;301:855-858.
12. Hull RD, Delmore T, Carter C, Hirsh J, Genton E, Gent M, Turpie AGG, McLoughlin D: Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982;306:189-194.
13. Hull RD, Hirsh J, Jay R, Carter C, England C, Gent M, Turpie AGG, McLoughlin D, Dodd P, Raskob G, Ockleford P: Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982;307:1676-1681.
14. Gallus AS, Jackaman J, Tillett J, Mills W, Wycherley A: Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986;2:1293-1296.
15. Hull RD, Raskob GE, Rosenbloom D, Panju AA, Brill-Edwards P, Ginsberg JS, Hirsh J, Martin GJ, Green D: Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990;322:1260-1264.
16. Brandjes DPM, Heijboer H, Buller HR, de Rijk M, Jugt H, ten Cate JW: Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992;327:1485-1489.
17. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HR: Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-982.
18. Prandoni P, Lensing AWA, Buller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten Cate JW: Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441-445.
19. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srivivas S: The weight-based heparin dosing nomogram compared with a 'standard care' nomogram: a randomized controlled trial. Ann Intern Med 1993;119:874-881.
20. Salzman EW: Low-molecular-weight heparin: Is small beautiful? N Engl J Med 1986;315:957-959.
21. Verstraete M: Pharmacotherapeutic aspects of unfractionated and low molecular weight heparin. Drugs 1990;40:498-530.
22. Bergqvist D, Hedner U, Sjorin E, Holmer E: Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously. Thromb Res 1983;32:381-391.
23. Bara L, Billaud E, Gramond G, Kher A, Samama M: Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985;39:631-636.
24. Bratt G, Tornebohm E, Widlund L, Lockner D: Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 1986;42:613-620.
25. Harenberg J, Wurzner B, Zimmermann R, Schettler G: Bioavailability and antagonization of the low molecular weight heparin CY 216 in man. Thromb Res 1986;44:549-554.
26. Frydman AM, Bara L, Le Roux Y, Woler M, Chauliac F, Samama MM: The antithrombotic activity and pharmacokinetics of enoxaparin, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol 1988;28:609-618.
27. Matzsch T, Bergqvist D, Hedner U, Ostergaard P: Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers. Thromb Haemost 1987;57:97-101.
28. Aiach M, Michaud A, Balian J-L, Lefebre M, Woler M, Fourtillan JB: A new low molecular weight heparin derivative: in vitro and in vivo studies. Thromb Res 1983;31:611-621.
29. Siegbahn A, Y-Hassan S, Boberg J, Bylund H, Neerstrand HS, Ostergaard P, Hedner U: Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin: a dose finding study with LMWH-Novo. Thromb Res 1989;55:767-778.
30. Weinstein MC: Economic assessment of medical practices and technologies. Med Decis Making 1981;1:309-330.
31. Weinstein MC, Stason WB: Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977;296:716-721.
32. Department of Clinical Epidemiology and Biostatistics, McMaster University: How to read clinical journals, VIII: to understand an economic evaluation. Can Med Assoc J 1984;130:1428-1434, 1542-1549.
33. Drummond MF, Stoddart GL, Torrance GW: Methods for the Economic Evaluation of Health-Care Programs. New York, NY: Oxford University Press Inc;1987.
34. Eddy DM: Principles for making difficult decisions in difficult times. JAMA 1994;271:1792-1798.
35. Eisenberg JM: Clinical economics: a guide to economic analysis of clinical practices. JAMA 1989;262:2879-2886.
36. Detsky AS, Naglie IG: A clinician's guide to cost effectiveness analysis. Ann Intern Med 1990;113:147-154.
37. Hillman AL, Eisenberg JM, Pauly MV, Bloom BS, Glick H, Kinosian B, Schwartz JS: Sounding board: avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 1991;324:1362-1365.
38. Kassirer JP, Angell M: The journal's policy on cost-effectiveness analyses. N Engl J Med 1994;331:669-670.
39. Hull RD, Raskob GE, Rosenbloom D, Pineo GF, Lerner RG, Gafni A, Trowbridge AA, Elliott CG, Green D, Feingles J, Feldstein W, Brant R: Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. Arch Int Med 1997;157:289-294.
40. Hull RD, Hirsh J, Carter C, Raskob GE, Gill GJ, Jay RM, Leclerc JR, David M, Coates G: Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. Chest 1985;88:819-828.
41. The PIOPED Investigators: Value of the ventilation/perfusion scan in acute pulmonary embolism: results of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED). JAMA 1990;263:2753-2759.
42. Bookstein JJ, Silver TM: The angiographic differential diagnosis of acute pulmonary embolism. Radiology 1974;110:25-33.
43. Rajan R, Gafni A, Levine M, Hirsh J, Gent M: Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: and economic evaluation. J Clin Oncol 1995;13:42-46.
44. Simon G, Wagner E, Vonkorff M: Cost-effectiveness comparisons using 'real world' randomized trials: the case of new antidepressant drugs. J Clin Epidemiol 1995;48:363-373.
45. Weinmann E, Salzman EW: Medical progress: deep-vein thrombosis. N Engl J Med 1994;331:1630-1641.
46. Coon WW, Willis PW 3rd, Symons MJ: Assessment of anticoagulant treatment of venous thromboembolism. Ann Surg 1969;170:559-568.
47. Eddy DM: Three battles to watch in the 1990s. JAMA 1993;270:520-526.
48. Gafni A, Birch S: Cost-effectiveness/utility analyses: do current decision rules lead us to where we want to be? J Health Econ 1992;11:279-296.
49. Gafni A, Birch S: Guidelines for the adoption of new technology: a prescription for uncontrolled growth in expenditures and how to avoid it. Can Med Assoc J 1993;148:913-917.
50. Nightingale SL: Appropriate use of low-molecular-weight heparin (LMWHs). JAMA 1993;270:1672.
51. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AGG, Demers C, Kovacs M: A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-681.
52. Koopman M, Prandoni P, Piovella F, Ockleford PA, Brandjes DPM, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH, Bossuyt PMM, de Haes H, van den Belt AGM, Sagnard L, d'Azemar P, Buller HR: Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-687.
53. The Columbus Investigators: Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657-662.
54. van den Belt AGM, Bossuyt PMM, Prins MH, Gallus AS, Buller HR: Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis - and economic evaluation. TASMAN Study Group. Thromb Haemost 1998;79:259-263.